FDA warns Abbott Diabetes Care that FreeStyle Libre 3 glucose monitors lacked design transfer and finished-device accuracy release testing.
What happened
During an inspection at Abbott's Alameda, CA facility from October 14 to October 23, 2025, FDA found that Abbott did not transfer glucose accuracy specifications to third-party manufacturers and did not test finished, sterilized, packaged FreeStyle Libre devices for accuracy before release. FDA reviewed Abbott's responses dated November 14 and December 19, 2025, and found them inadequate.
What FDA found
Abbott did not have adequate procedures to move design performance requirements into production specifications for third-party manufacturers.
21 CFR 820.30(h)Abbott released finished FreeStyle Libre devices without testing fully assembled, sterilized, programmed, and packaged devices for glucose accuracy before distribution.
21 CFR 820.80(d)Abbott did not establish statistically valid acceptance criteria and sampling plans for finished-device release.
21 CFR 820.250(a)Abbott did not adequately prove that its manufacturing and release control preserves the device's accuracy performance.
21 CFR 820.30(g); 21 CFR 862.1355(b)(3)
What FDA wants
FDA asks Abbott to respond in writing within 15 business days with specific corrections and corrective actions to address the violations and prevent recurrence, including a timetable if work will take longer.
Who should pay attention
- patients who use FreeStyle Libre glucose monitors
- healthcare providers who rely on continuous glucose monitoring readings
- contract manufacturers and distributors of finished glucose monitoring devices
This is a summary. Read the original letter on fda.gov.